



**LEI: 549300Q7EXQQH6KF7Z84**

4 December 2025

**RTW Biotech Opportunities Ltd**  
**Inclusion in FTSE 250 Index**

RTW Biotech Opportunities Ltd ("RTW Bio"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to announce that its Ordinary Shares will be included in the FTSE 250 Index. This will be effective at the opening of trading today. This follows the inclusion of RTW Bio's shares in the FTSE All-Share Index from 22 September 2025.

Commenting on this development, William Simpson, Chair of RTW Bio, said:

"We are delighted that RTW Bio's Ordinary Shares will be included in the FTSE 250 Index from the opening of trading today. This constitutes another major milestone for RTW Bio and reflects the positive momentum delivered by the team to date, with the share price up 43% year-to-date and NAV performance ahead of key biotech indices and our peer group. We look forward to building upon this, with inclusion in the FTSE 250 Index likely to further enhance liquidity in our shares, deepen our investor base, and develop greater UK and international investor awareness of RTW Bio."

**Enquiries:**

**RTW Investments, LP - Investment Manager** +44 (0)20 7959 6362  
Oliver Kenyon  
Woody Stileman  
Krisha McCune (Investor Relations) [biotechopportunities@rtwfunds.com](mailto:biotechopportunities@rtwfunds.com)

**Cadarn Capital - PR & IR Partner** +44 (0)7984 184 461 / [lucy@cadarncapital.com](mailto:lucy@cadarncapital.com)  
Lucy Clark (PR)  
David Harris (Distribution) +44 (0)7368 883 211 / [david@cadarncapital.com](mailto:david@cadarncapital.com)

**Deutsche Numis - Joint Corporate Broker** +44 (0)20 7260 1000  
Freddie Barnfield  
Nathan Brown  
Duncan Monteith

**BofA Securities - Joint Corporate Broker** +44 (0)20 7628 1000  
Edward Peel  
Alex Penney

**Altum (Guernsey) Limited** +44 (0)1481 703 100  
Joanna Duquemin Nicolle  
Sadie Morrison

**About RTW Biotech Opportunities Ltd:**

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at [www.rtwfunds.com/rtw-biotech-opportunities-ltd](http://www.rtwfunds.com/rtw-biotech-opportunities-ltd) for more information.

\*\*\*\*\*

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well

as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

\*\*\*\*\*

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFSEEFDEISESE